Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
A Japan-based joint venture between Takeda Pharmaceutical and Teva Holdings aims to become a number one player in what it describes as the “off-patent drug” market, which combines generics and long-listed brand-name products, in 2020 or later, CEO and President…
To read the full story
Related Article
- Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
- There Will Be Consolidation in Japan Generic Space: Teva Exec
October 11, 2016
- CEO of Teva-Takeda JV Confident on Handling Both Long-Listed Brands, Generics
August 17, 2016
- Teva JV Deal Marks Turning Point in Takeda’s Japanese Business
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
- Takeda to Set Up Generic JV with Teva, Transfer Long-Listed Products
December 1, 2015
- Takeda, Teva Hook Up to Form Generic Joint Venture in Japan
November 30, 2015
BUSINESS
- Lunsumio Combo Hits PIII Goal in Follicular Lymphoma: Roche
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- SanBio Eyes October Start for Akuugo Treatment
September 18, 2026
- Toho Unit to Launch Pharma-Wholesaler Payment Service
September 18, 2026
- Astellas Names Marino General Counsel, Compliance Chief
September 18, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…